Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.
about
Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approachMethods to assess cost-effectiveness and value of further research when data are sparse: negative-pressure wound therapy for severe pressure ulcers.Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.Expected value of sample information for Weibull survival data.Estimating expected value of sample information for incomplete data models using Bayesian approximation.Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in ThailandIntensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysisUrological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines.Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.Strategies for efficient computation of the expected value of partial perfect information.Accounting for uncertainty in health economic decision models by using model averaging.Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression MetamodelingDecision analysis for resource allocation in health care.Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes.A systematic and critical review of the evolving methods and applications of value of information in academia and practice.A practical guide to value of information analysis.The role of value-of-information analysis in a health care research priority setting: a theoretical case study.Expected net present value of sample information: from burden to investment.The half-life of truth: what are appropriate time horizons for research decisions?Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods.Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.Linear regression metamodeling as a tool to summarize and present simulation model results.Value of Information: We've Got Speed, What More Do We Need?Calculating partial expected value of perfect information via Monte Carlo sampling algorithms.
P2860
Q27324994-94B94136-7F43-43DC-9977-4BC873FE4A06Q30559593-1CC02E04-ED63-4B46-8E21-C7FFA308430CQ30651607-3F43E61A-BFC3-4C22-8A2E-753D3B65823DQ31103156-F4AE38CF-E50F-4266-BFDE-99F78AD455ABQ33879453-AE56BED7-9F76-4D20-8A73-464265DF637AQ33951023-2C5883C1-52D7-45B4-844B-1E8C733D6FEBQ34146085-F97E1A12-6DB3-4EF7-8197-6D5C3EC16F9BQ34996375-00DFB871-99EB-44C9-B62B-4270343479BFQ36469022-6587F1C5-4CB6-4B15-960E-A68D5E0F2524Q37103266-F5FD4589-B4B3-476A-AD61-A8DFBA88614EQ37154331-E8A0382D-FB9E-446D-8378-1A90DC9ABC7BQ37163118-E9F05D89-AD56-49DE-987A-E6F319C38656Q37275135-E55ADD69-5B70-4268-A415-6A2D42976E4BQ37768239-52426A13-4082-4C5E-BD2E-1C224CC0B760Q38074914-ED93B1EB-2247-4187-9B00-71EF3F70962CQ39109596-32429227-CF21-4455-B605-61E2A609433EQ39494022-FFCFA09D-D659-41FE-A914-5D8BA0E6C370Q39623036-ACF97A3F-3CA4-45A8-8F40-C8E656E629D5Q40096855-CE20E74D-8643-4789-A928-B373B378C823Q40360668-9B06E6DB-76EF-4D5F-899D-2B2160A924A2Q43255273-DA8C07C8-70EB-415C-8DBC-10EF8F8BB4E0Q46095018-647449C6-412F-42AA-BC18-570E2060BAB0Q50939811-2221124F-8100-4E56-AAC2-DF0E1E861BB3Q51625586-2141A08A-5191-494D-89DA-E1D40EAE4B29
P2860
Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Methods for expected value of ...... cetate for multiple sclerosis.
@ast
Methods for expected value of ...... cetate for multiple sclerosis.
@en
type
label
Methods for expected value of ...... cetate for multiple sclerosis.
@ast
Methods for expected value of ...... cetate for multiple sclerosis.
@en
prefLabel
Methods for expected value of ...... cetate for multiple sclerosis.
@ast
Methods for expected value of ...... cetate for multiple sclerosis.
@en
P2093
P356
P1476
Methods for expected value of ...... cetate for multiple sclerosis.
@en
P2093
Chilcott JB
Eggington S
Tappenden P
P304
P356
10.3310/HTA8270
P577
2004-06-01T00:00:00Z